Tropomyosin-related kinase A is a protein with high affinity for nerve growth factor (NGF), which mediates the multiple effects of NGF including neuronal differentiation, nociceptor response, and avoidance of programmed cell death. TrkA receptor inhibitors act by blocking the binding of NGF to the TrkA receptor. TrkA inhibitors are indicated for colorectal cancer, gastrointestinal stromal tumors, liver cancer, non-small cell lung cancer, solid tumors and thyroid cancer. Moreover, several clinical studies are being conducted for TrkA inhibitors for conditions like neuropathic pain, arthritis, atopic dermatitis, dry eye, and others. Bayer, Exelixis, Roche, Betta Pharmaceuticals, and Blueprint Medicines are the key players with approved drugs in the market. Sanofi, Pfizer, Astellas, AlzCure, Eisai and Mirati Therapeutics, are some of the pharmaceutical companies with TkrA receptor inhibitors in their pipeline.
Key Market Developments:
- In Apr 2023, Blueprint Medicines and Roche’s Pralsetinib (Gavreto) was registered for thyroid cancer in Australia.
- In May 2023, Blueprint Medicines and Roche’s Pralsetinib (Gavreto) got preregistration for non-small lung cancer as first-line therapy in China.
- In Dec 2022, Tiziana Life Sciences filed an IND application with the US FDA for non-small cell lung cancer for Milciclib maleate (TZLS-201).
Approved Drug Molecules and Brand Names for Tropomyosin-related kinase A (TrkA) Receptor Inhibitors:
- Stivarga (Regorafenib)
- Cometriq (Cabozantinib capsule)
- Rozlytrek (Entrectinib)
- Ensacove (Ensartinib)
- Vitrakvi (Larotrectinib)
- Gavreto (Pralsetinib)
Drugs under the Pipeline for Tropomyosin-related kinase A (TrkA) Receptor Inhibitors:
- Sitravatinib (MGCD516)
- Pegcantratinib (SNA-120)
- Taletrectinib (AB-106)
- Milciclib (TZLS-201)
- Repotrectinib (TPX-0005)
- VIC-1911
- PBI-200
- PF-06273340
- Rebastinib (DCC-2036)
- Selitrectinib (BAY 2731954)
- ASP7962
- E2511
- GZ389988
- ONO-4474
- TQB3558
- VC004
- Belizatinib (TSR-011)
- AUM-601
- BPI-28592
- FCN-098
- GBR 900
- HH-30134
- ONO-7579
- OPN-7486
- SIM1803-1A
- TQB3811
- TSN084
- TY-2136b
- VMD-928
- XZP-5955
- Altiratinib (DCC-2701)
Clinical Activity and Developments of Tropomyosin-related kinase A (TrkA) Receptor Inhibitors:
Currently, there are 39 products in TrkA inhibitors, including about 6 approved drug products and more than 30 drug molecules are in clinical trial phases.
- In Nov 2022, Pyramid Biosciences completed a phase-I pharmacokinetics trial in the USA in volunteers for PBI200, a TrkA antagonist.
- In Apr 2023, TYK Medicine conducted a phase-I clinical trial in solid tumor patients as second-line therapy in the USA for TY 2136, a TrkA inhibitor.
|
Molecule Name |
Number of Studies |
|
Sitravatinib (MGCD516) |
36 |
|
Pegcantratinib (SNA-120) |
10 |
|
Taletrectinib (AB-106) |
8 |
|
Milciclib (TZLS-201) |
7 |
|
Repotrectinib (TPX-0005) |
7 |
|
VIC-1911 |
6 |
|
PBI-200 |
5 |
|
PF-06273340 |
4 |
|
Rebastinib (DCC-2036) |
4 |
|
Selitrectinib (BAY 2731954) |
4 |
|
ASP7962 |
3 |
|
E2511 |
2 |
|
GZ389988 |
2 |
|
ONO-4474 |
2 |
|
TQB3558 |
2 |
|
VC004 |
2 |
|
Belizatinib (TSR-011) |
2 |
|
AUM-601 |
1 |
|
BPI-28592 |
1 |
|
FCN-098 |
1 |
|
GBR 900 |
1 |
|
HH-30134 |
1 |
|
ONO-7579 |
1 |
|
OPN-7486 |
1 |
|
SIM1803-1A |
1 |
|
TQB3811 |
1 |
|
TSN084 |
1 |
|
TY-2136b |
1 |
|
VMD-928 |
1 |
|
XZP-5955 |
1 |
|
Altiratinib (DCC-2701) |
1 |
Target Indication Analysis of Tropomyosin-related kinase A (TrkA) Receptor Inhibitors
Bayer HealthCare’s Stivarga (Regorafenib) is used in the treatment of colorectal cancer, gastrointestinal stromal tumors, liver cancer, also it is in phase-III for glioblastoma, and in phase-II for adenoid cystic carcinoma, biliary cancer, ovarian cancer, pancreatic cancer, and others. Roche’s Rozlytrek (Entrectinib) is indicted for non-small cell lung cancer and solid tumors, in phase-II for brain metastases and malignant melanoma, and is in phase-I/II for uveal melanoma. Blueprint Medicines’s Gavreto (Pralsetinib) is in the market for the treatment of non-small cell lung cancer and thyroid cancer, and in phase-II for solid tumors.
Regional Analysis of Tropomyosin-related kinase A (TrkA) Receptor Inhibitors
Tropomyosin-related kinase A Receptor Inhibitors Market
Bayer’s Stivarga (Regorafenib) had a total sale of US$ 520 million in 2021 and witnessed an increase to US$ 669 million in 2022 and its another TrkA inhibitor will see its patent expiration across various countries like Germany, France, Italy, Switzerland, and others by 2034. Globally, cancer is the 2nd leading cause of mortality after cardiovascular diseases, and it is the leading cause of death in over 50 countries. According to the World Health Organization’s report on cancer in 2020, about 5,55,477 new colorectal new cancer cases were recorded in China, followed by the USA with 1,55,008 new cases. In the case of liver cancer, 4,10,038 new cases in China and 45,663 new cases in Japan were recorded. Lung cancer being the most common cancer, had 8,15,563 new cases in China and 2,27,875 new cases in the USA. Also, for thyroid cancer, China had 2,21,093 new cases, followed by the USA with 52,912 new cases in 2020.
Latin America
Europe
Asia Pacific
Middle East
North America
Key Features of the Reports
- The report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
- The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
- The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
- The report tracks recent innovations, key developments, and start-up details that are actively working in the market
- The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
Frequently Asked Questions
Stivarga (Regorafenib), Cometriq (Cabozantinib capsule), Rozlytrek (Entrectinib), Ensacove (Ensartinib), Vitrakvi (Larotrectinib), Gavreto (Pralsetinib) are the approved Tropomycin-related kinase A (TrkA) Receptor inhibitors.
Stivarga (Regorafenib) had a total sale of US$ 669 million in 2022.
Bayer, Exelixis, Roche, Betta Pharmaceuticals, and Blueprint Medicines are the major players with approved drugs in the market in the Tropomycin-related kinase A (TrkA) Receptor inhibitors.
Major indications for Tropomycin-related kinase A (TrkA) Receptor inhibitors are colorectal cancer, gastrointestinal stromal cancer, solid tumor, thyroid cancer, and non-small cell lung cancer.
- Bayer (Germany)
- Exelixis (USA)
- Mirati Therapeutics (USA)
- Roche (Switzerland)
- Blueprint Medicines (USA)
- Tiziana Life Sciences (USA)
- VITRAC Therapeutics (USA)
- Pyramid Biosciences (USA)
- Pfizer (USA)
- AlzeCure Pharma (Sweden)
- Astellas Pharma (Japan)
- Eisai (Japan)
- Sanofi (France)
- Ono Pharmaceutical (Japan)
- Betta Pharmaceuticals (Japan)
- Glenmark Pharmaceuticals (India)
- Sino Biopharm (Japan)
- TYK Medicines (Japan)